July 2024 in “Journal of Investigative Dermatology” Baicalin may help treat severe drug-induced skin reactions.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
45 citations
,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
7 citations
,
March 2002 in “AIDS” Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
69 citations
,
July 1997 in “Der Urologe” Sabal and Urtica extract works as well as finasteride for treating BPH, with fewer side effects.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
5 citations
,
January 2021 in “Daru” A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
54 citations
,
February 1994 in “Journal of Investigative Dermatology”
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
April 2016 in “Journal of The American Academy of Dermatology” Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
9 citations
,
June 2014 in “Nutrition and Cancer” Eclipta alba extract may work as an anticancer agent and help reverse drug resistance.
January 2026 in “Food Science and Human Wellness” Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
41 citations
,
March 2007 in “Journal of dermatological science” Taking L-cystine and vitamin B6 can prevent hair loss caused by smoke in mice.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
3 citations
,
October 1993 in “Endocrinology”
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
34 citations
,
July 1993 in “PubMed”
1 citations
,
November 2020 in “International Journal of Dermatology” Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.